# Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

> **NCT01458548** · PHASE2 · TERMINATED · sponsor: **Charite University, Berlin, Germany** · enrollment: 70 (actual)

## Conditions studied

- Post-transplantation Lymphoproliferative Disorder

## Interventions

- **DRUG:** Rituximab
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT01458548
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-12
- **Primary completion:** 2008-05
- **Final completion:** 2011-10
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** This study had an major amendment in 12/2006 introducing risk stratified sequential treatment (RSST). The modified protocol is registered with NCT00590447.
- **Last updated:** 2011-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458548, "Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01458548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*